MacroGenics Announces Positive Interim Results of Phase 2 LINNET for Lorigalimab in Advanced Clear Cell Gynecologic Cancer.
MacroGenics Announces Positive Interim Results of Phase 2 LINNET for Lorigalimab in Advanced Clear Cell Gynecologic Cancer.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in